NCT07166315View on ClinicalTrials.gov

Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor

RecruitingOBSERVATIONAL

Enrollment

700

Participants

Timeline

Start Date

July 7, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions

Axial Spondylarthritis (axSpA)Psoriatic Arthritis (PsA)

Interventions

OTHER

observational study

This is an observational study based on existing treatments prescribed prior to inclusion. No interventions are given as part of this research.

Trial Locations (1)

BA1 3NG

RECRUITING

Royal National Hospital for Rheumatic Diseases, Bath

All Listed Sponsors

lead

Adelphi Real World

INDUSTRY

NCT07166315 - Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor | Biotech Hunter | Biotech Hunter